back to US directory
us clinical guidance

Daridorexant for adult insomnia

US FDA-label boundaries for daridorexant placed within CBT-I-first chronic-insomnia assessment and follow-up.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with insomnia characterized by difficulty initiating or maintaining sleep. Daridorexant is an FDA-approved Schedule IV orexin-receptor antagonist, but approval does not make it first-line for every patient.
sources for this section:FDA QUVIVIQ labelVA/DoD insomnia 2025

The Bottom Line

  • Confirm chronic insomnia and address sleep opportunity, schedule, other sleep disorders, medicines, substances and mental-health conditions before considering daridorexant.
  • Offer CBT-I first because the VA/DoD guideline prefers CBT-I over pharmacotherapy; use medication only after an individualized discussion of likely benefit, burden, alternatives and patient preference.
  • Use the current US prescribing information for dose, timing, hepatic impairment and CYP3A interaction decisions.
  • Measure both nighttime symptoms and daytime function after initiation, and stop or change treatment when benefit is insufficient, adverse effects are unacceptable or the underlying diagnosis remains uncertain.
sources for this section:FDA QUVIVIQ labelVA/DoD insomnia 2025

Practical clinical workflow

1
Document sleep onset, awakenings, total sleep opportunity, daytime impairment, prior CBT-I, OSA and narcolepsy symptoms, parasomnias, mood, suicidality, alcohol, cannabis and all sedating medicines.
2
Check the current label for contraindications, CYP3A inhibitors or inducers, hepatic function, respiratory compromise and the required interval available for sleep before issuing a prescription.
3
Explain possible next-day impairment, somnolence or fatigue, headache, sleep paralysis, hallucination-like sleep-transition experiences and complex sleep behavior in plain language.
4
Review early and periodically for benefit, alertness, driving safety, mood, misuse and interaction; reassess comorbid diagnoses when insomnia persists rather than escalating hypnotics reflexively.
sources for this section:FDA QUVIVIQ labelVA/DoD insomnia 2025

Safety boundaries and escalation

  • Daridorexant is contraindicated in narcolepsy and should not be taken when the patient cannot remain in bed for the label-required sleep interval.
  • Combining it with alcohol or other central nervous system depressants increases impairment risk; caution about next-day driving and other tasks requiring full alertness.
  • Stop the medicine and urgently review complex sleep behaviors; promptly assess worsening depression, suicidal thinking, severe hypersensitivity or clinically important respiratory deterioration.
  • Use particular caution with compromised respiratory function and hepatic impairment and verify every interaction against the live label because product information can change.
sources for this section:FDA QUVIVIQ label

Localization

Schedule IV prescribing, formulary authorization and coverage vary by federal and state rules and insurer.
sources for this section:FDA QUVIVIQ labelVA/DoD insomnia 2025

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea2025 guideline 路 published 2025-01-01 路 accessed 2026-08-20
    view source
  2. U.S. Food and Drug AdministrationQUVIVIQ (daridorexant) tablets, current US prescribing informationDrugs@FDA NDA 214985; current FDA-submitted label checked 2026-08-20 路 updated 2026-02-26 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.